articleThe LancetJun 1, 2003Closed access

Paclitaxel plus platinum-based chemotherapy versus conventional platinum-based chemotherapy in women with relapsed ovarian cancer: the ICON4/AGO-OVAR-2.2 trial

MPMahesh ParmarJAJonathan A. LedermannNCNicoletta ColomboADAndreas du BoisDJDelaloye Jf
PubMed
Indexed incrossrefpubmed

Abstract

No abstract available for this paper.

Citation impact

1,195
total citations
FWCI
66.49
Percentile
100%
References
20
Citations per year

Authors

15

Topics & keywords

Topics
Keywords
  • Medicine
  • Chemotherapy
  • Paclitaxel
  • Hazard ratio
  • Internal medicine
  • Ovarian cancer
  • Progression-free survival
  • Oncology
UN Sustainable Development Goals
  • Good health and well-being
No related works found for this paper.

Funding